Targeting hexokinase 2 enhances response to radio-chemotherapy in glioblastoma

First-line cancer therapies such as alkylating agents and radiation have limited survival benefits for Glioblastoma (GBM) patients. Current research strongly supports the notion that inhibition of aberrant tumor metabolism holds promise as a therapeutic strategy when used in combination with radiati...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Oncotarget
Main Authors: Vartanian, Alenoush, Agnihotri, Sameer, Wilson, Mark R., Burrell, Kelly E., Tonge, Peter D., Alamsahebpour, Amir, Jalali, Shahrzad, Taccone, Michael S., Mansouri, Sheila, Golbourn, Brian, Aldape, Kenneth D., Zadeh, Gelareh
Formato: Artigo
Idioma:Inglês
Publicado: Impact Journals LLC 2016
Assuntos:
Research Paper
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5342495/
https://ncbi.nlm.nih.gov/pubmed/27588472
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.11680
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares